Intellia Therapeutics Inc NTLA

NAS: NTLA | ISIN: US45826J1051   3/05/2024
23,60 USD (+1,42%)
(+1,42%)   3/05/2024

18 oktober 2023 · Thinking about trading options or stock in Palantir Technologies, Macy's, Intellia Therapeutics, Shopify, or Brinker International? · Persbericht

16 september 2022 · Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis · Persbericht

24 juni 2022 · Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose · Persbericht

28 februari 2022 · Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein · Persbericht

26 juni 2021 · Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis · Persbericht

10 maart 2021 · Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium · Persbericht

25 februari 2021 · Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results · Persbericht

7 januari 2021 · Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 · Persbericht

Mijn selecties